九游会·J9-中国官方网站|真人游戏第一品牌

Luye Pharma’s Innovative Formulation LY03003 Meets Primary Endpoints in Phase III Clinica...

The world’s first drug that can produce long-term Continuous Dopaminergic Stimulation

Luye Pharma’s Innovative Drug Lurbinectedin Approved for Urgent Clinical Use in Hainan

Providing a new option for SCLC patients

Phase III Clinical Trial Results of Luye Pharma’s Investigational Drug LY03005 Presented ...

Marketing Authorization Application for Luye Pharma’s Rivastigmine Twice Weekly Transderm...

The product has already received marketing authorization in multiple European countries.

Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer...

Luye Pharma’s LY03005 Approved by China’s CDE to Conduct Phase III Clinical Trial for th...